Cargando…
Safety and efficacy of an interleukin 12/23 inhibitor in a patient with constitutional neutropenia and psoriasis vulgaris()()
Autores principales: | Starek, Jéssica Vianna, Bechara, Cristina Santos Ribeiro, Dultra, Mariana Reis e Rocha, Krakheche, Juliana de Morais Fernandes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790215/ https://www.ncbi.nlm.nih.gov/pubmed/34544636 http://dx.doi.org/10.1016/j.abd.2020.11.010 |
Ejemplares similares
-
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
por: Lee, Edmund, et al.
Publicado: (2004) -
Plasma Interleukin-18 and Dendritic Cells in Males with Psoriasis Vulgaris
por: Pietrzak, Aldona, et al.
Publicado: (2007) -
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010) -
Inhibition of interleukin‐12 and/or interleukin‐23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
por: Ergen, Elizabeth N., et al.
Publicado: (2018) -
Overexpression of Interleukin-23 and Interleukin-17 in the Lesion of Pemphigus Vulgaris: A Preliminary Study
por: Xue, Jixin, et al.
Publicado: (2014)